260 related articles for article (PubMed ID: 38398394)
1. Unmet Horizons: Assessing the Challenges in the Treatment of
Stafylidis C; Vlachopoulou D; Kontandreopoulou CN; Diamantopoulos PΤ
J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398394
[TBL] [Abstract][Full Text] [Related]
2. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.
Daver NG; Maiti A; Kadia TM; Vyas P; Majeti R; Wei AH; Garcia-Manero G; Craddock C; Sallman DA; Kantarjian HM
Cancer Discov; 2022 Nov; 12(11):2516-2529. PubMed ID: 36218325
[TBL] [Abstract][Full Text] [Related]
3.
Shin DY
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835510
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
Venugopal S; Shoukier M; Konopleva M; Dinardo CD; Ravandi F; Short NJ; Andreeff M; Borthakur G; Daver N; Pemmaraju N; Sasaki K; Montalban-Bravo G; Marx KR; Pierce S; Popat UR; Shpall EJ; Kanagal-Shamanna R; Garcia-Manero G; Kantarjian HM; Kadia TM
Cancer; 2021 Oct; 127(19):3541-3551. PubMed ID: 34182597
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
Kim K; Maiti A; Loghavi S; Pourebrahim R; Kadia TM; Rausch CR; Furudate K; Daver NG; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Tang G; Ravandi F; Kantarjian HM; DiNardo CD; Konopleva MY
Cancer; 2021 Oct; 127(20):3772-3781. PubMed ID: 34255353
[TBL] [Abstract][Full Text] [Related]
6. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
Barbosa K; Li S; Adams PD; Deshpande AJ
Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
[TBL] [Abstract][Full Text] [Related]
7. TP53 signal pathway confers potential therapy target in acute myeloid leukemia.
Zhu G; Cai J; Zhong H
Eur J Haematol; 2023 May; 110(5):480-489. PubMed ID: 36692074
[TBL] [Abstract][Full Text] [Related]
8. Current status and new treatment approaches in TP53 mutated AML.
Hunter AM; Sallman DA
Best Pract Res Clin Haematol; 2019 Jun; 32(2):134-144. PubMed ID: 31203995
[TBL] [Abstract][Full Text] [Related]
9. TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation.
Zhao D; Zarif M; Zhou Q; Capo-Chichi JM; Schuh A; Minden MD; Atenafu EG; Kumar R; Chang H
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370821
[No Abstract] [Full Text] [Related]
10.
Molica M; Mazzone C; Niscola P; de Fabritiis P
Front Oncol; 2020; 10():610820. PubMed ID: 33628731
[No Abstract] [Full Text] [Related]
11. Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics.
Asghari H; Talati C
Curr Opin Hematol; 2020 Mar; 27(2):66-75. PubMed ID: 31922971
[TBL] [Abstract][Full Text] [Related]
12.
Ball S; Loghavi S; Zeidan AM
Leuk Lymphoma; 2023 Mar; 64(3):540-550. PubMed ID: 36323304
[TBL] [Abstract][Full Text] [Related]
13. Are We Moving the Needle for Patients with
Shallis RM; Bewersdorf JP; Stahl MF; Halene S; Zeidan AM
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626039
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional profiling demonstrates altered characteristics of CD8
Abolhalaj M; Sincic V; Lilljebjörn H; Sandén C; Aab A; Hägerbrand K; Ellmark P; Borrebaeck CAK; Fioretos T; Lundberg K
Cancer Med; 2022 Aug; 11(15):3023-3032. PubMed ID: 35297213
[TBL] [Abstract][Full Text] [Related]
15. [Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].
Kojima K
Rinsho Ketsueki; 2023; 64(9):955-961. PubMed ID: 37793871
[TBL] [Abstract][Full Text] [Related]
16. TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Marvin-Peek J; Mason EF; Kishtagari A; Jayani RV; Dholaria B; Kim TK; Engelhardt BG; Chen H; Strickland S; Savani B; Ferrell B; Kassim A; Savona M; Mohan S; Byrne M
Transplant Cell Ther; 2023 Jun; 29(6):390.e1-390.e10. PubMed ID: 36906277
[TBL] [Abstract][Full Text] [Related]
17. DRP1 Inhibition Enhances Venetoclax-Induced Mitochondrial Apoptosis in TP53-Mutated Acute Myeloid Leukemia Cells through BAX/BAK Activation.
Jang JE; Hwang DY; Eom JI; Cheong JW; Jeung HK; Cho H; Chung H; Kim JS; Min YH
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765703
[TBL] [Abstract][Full Text] [Related]
18. Advances in the pharmacological management of acute myeloid leukemia in adults.
Numan Y; Abaza Y; Altman JK; Platanias LC
Expert Opin Pharmacother; 2022 Sep; 23(13):1535-1543. PubMed ID: 35938317
[TBL] [Abstract][Full Text] [Related]
19. Patterns of mutations in TP53 mutated AML.
Welch JS
Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes.
Kadia TM; Jain P; Ravandi F; Garcia-Manero G; Andreef M; Takahashi K; Borthakur G; Jabbour E; Konopleva M; Daver NG; Dinardo C; Pierce S; Kanagal-Shamanna R; Patel K; Estrov Z; Cortes J; Kantarjian HM
Cancer; 2016 Nov; 122(22):3484-3491. PubMed ID: 27463065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
